Australian Pharmaceutical Industries Ltd
ASX:API
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zhejiang Huasheng Technology Co Ltd
SSE:605180
|
CN |
|
Hindware Home Innovation Ltd
NSE:HINDWAREAP
|
IN |
|
T
|
Tata Steel Ltd
LSE:TTST
|
IN |
|
S
|
Synspective Inc
TSE:290A
|
JP |
|
D
|
Digihost Technology Inc
XTSX:DGHI
|
CA |
|
IAMGOLD Corp
TSX:IMG
|
CA |
|
M
|
Miraculum SA
WSE:MIR
|
PL |
|
Bravida Holding AB
STO:BRAV
|
SE |
|
N
|
NBTM New Materials Group Co Ltd
SSE:600114
|
CN |
|
B
|
BBB Foods Inc
NYSE:TBBB
|
MX |
|
N
|
Nouveau Monde Graphite Inc
NYSE:NMG
|
CA |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (41.1), the stock would be worth AU$1.53 (0% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 41.1 | AU$1.53 |
0%
|
| 3-Year Average | 41.1 | AU$1.53 |
0%
|
| 5-Year Average | 41.1 | AU$1.53 |
0%
|
| Industry Average | 25.5 | AU$0.95 |
-38%
|
| Country Average | 16.5 | AU$0.61 |
-60%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Australian Pharmaceutical Industries Ltd
ASX:API
|
753.8m AUD | 41.1 | 547.4 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
105.8B USD | 17.1 | 24.4 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
62.1B USD | 13.5 | 38.2 | |
| US |
|
Cencora Inc
NYSE:COR
|
60.8B USD | 13.3 | 37.4 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
48.8B USD | 14.2 | 29.3 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
30.1B AUD | 24.6 | 33.1 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
61B CNY | 14.8 | 10.8 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.3B USD | 10.3 | 21 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
58.8B CNY | 12.2 | 15.9 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 59.9 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
63B HKD | 0.6 | 7.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 16.5 |
| 70th Percentile | 24.5 |
| Max | 6 797.5 |
Other Multiples
Australian Pharmaceutical Industries Ltd
Glance View
Australian Pharmaceutical Industries Ltd. engages in the wholesale, product delivery, retail services, marketing programs and business advisory services. The company is headquartered in Melbourne, Victoria. The Company’s segments include Australia and New Zealand. The Australia segment is engaged in distribution of pharmaceutical, medical, health, beauty and lifestyle products and retail services to pharmacies, the purchase and sale of health, beauty and lifestyle products and services within the retail industry, including cosmetic products and non-invasive procedures. The New Zealand segment manufactures and owns rights for pharmaceutical medicines and consumer toiletries. The firm's brands include Priceline & Priceline Pharmacy, which is a health, beauty and wellbeing retailer; Soul Pattinson Chemist, which is a pharmacy brand; Pharmacist Advice, which offers professional service and advice; Club Premium, which is a club for independent pharmacies, and Pharmacy Best Buys, which offers a catalog program.
